![Paul Overton](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Paul Overton
Direttore/Membro del Consiglio presso SB Drug Discovery Ltd.
Posizioni attive di Paul Overton
Società | Posizione | Inizio | Fine |
---|---|---|---|
SB Drug Discovery Ltd.
![]() SB Drug Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sygnature Discovery Ltd., SB Drug Discovery Ltd. is a British company that specializes in ion channel services. The company is based in Glasgow, UK. The company offers a portfolio of electrophysiology assays and customized cell line development capabilities to aid in ion channel drug discovery. The company's services include ion channel screening, receptor and enzyme studies, and custom cell line generation expertise. The company also provides a comprehensive panel of sodium (Nav) channel cell lines and assays, as well as HTS and selectivity profiling services to advance hit-to-lead campaigns. The company was founded in 2002. SB Drug Discovery was acquired by Sygnature Discovery Ltd. on January 17, 2023. | Direttore/Membro del Consiglio | 16/12/2022 | - |
Storia della carriera di Paul Overton
Statistiche
Distribuzione geografica
Regno Unito | 2 |
Posizioni
Director/Board Member | 1 |
Settori
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
SB Drug Discovery Ltd.
![]() SB Drug Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sygnature Discovery Ltd., SB Drug Discovery Ltd. is a British company that specializes in ion channel services. The company is based in Glasgow, UK. The company offers a portfolio of electrophysiology assays and customized cell line development capabilities to aid in ion channel drug discovery. The company's services include ion channel screening, receptor and enzyme studies, and custom cell line generation expertise. The company also provides a comprehensive panel of sodium (Nav) channel cell lines and assays, as well as HTS and selectivity profiling services to advance hit-to-lead campaigns. The company was founded in 2002. SB Drug Discovery was acquired by Sygnature Discovery Ltd. on January 17, 2023. | Commercial Services |
- Borsa valori
- Insiders
- Paul Overton
- Esperienza